Indivior PLC (NASDAQ:INDV – Get Free Report)’s stock price traded up 3.9% on Thursday . The stock traded as high as $8.49 and last traded at $8.46. 95,739 shares changed hands during trading, a decline of 78% from the average session volume of 434,269 shares. The stock had previously closed at $8.14.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on INDV shares. Piper Sandler restated an “overweight” rating and issued a $15.00 price objective (down from $22.00) on shares of Indivior in a report on Friday, October 11th. Craig Hallum lowered their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, October 11th.
Read Our Latest Analysis on Indivior
Indivior Stock Performance
Indivior (NASDAQ:INDV – Get Free Report) last announced its earnings results on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The firm had revenue of $299.00 million during the quarter, compared to the consensus estimate of $285.90 million. Analysts anticipate that Indivior PLC will post 1.7 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Indivior
Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in shares of Indivior during the 2nd quarter valued at approximately $188,000. VELA Investment Management LLC acquired a new position in shares of Indivior in the second quarter worth $235,000. XTX Topco Ltd acquired a new stake in shares of Indivior in the second quarter worth about $249,000. Cubist Systematic Strategies LLC boosted its holdings in Indivior by 32.0% during the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after acquiring an additional 6,121 shares during the period. Finally, Cannon Global Investment Management LLC bought a new stake in shares of Indivior in the first quarter valued at about $563,000. 60.33% of the stock is owned by institutional investors and hedge funds.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
- Five stocks we like better than Indivior
- What does consumer price index measure?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Find and Profitably Trade Stocks at 52-Week Lows
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How to Calculate Stock Profit
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.